TABLE 1.
Primary genital herpes disease severity in guinea pigs treated with P-4010 or ACV
| Expt no. | No. of animals/ group | Treatment (dose and route)a | Value for parameter of clinical disease
|
Index of disease severityb | |||
|---|---|---|---|---|---|---|---|
| Duration of symptoms (days) | Mean total CLS/ guinea pigc | Mean IES/ guinea pigc | No. of days when CLS ≥ 10 | ||||
| 1 | 10 | P-4010 (40; i.p.) | 8.1 | 109.4*† | 0.30*‡ | 4.4 | 13.5 |
| ACV (20; i.p.) | 8.8 | 185.5 | 0.95 | 7.3 | 21.1 | ||
| Placebo (i.p.) | 9.1 | 223.3 | 1.29 | 7.4 | 24.5 | ||
| 3 | 10 | P-4010 (200; o.g.) | 8.4 | 54.1** | 0.26**† | 1.1 | 6.4 |
| ACV (100; o.g.) | 8.4 | 86.5 | 0.64 | 3.4 | 10.3 | ||
| Placebo (o.g.) | 9.4 | 115.4 | 0.67 | 4.1 | 12.2 | ||
| 4 | 16 | P-4010 (40; i.p.) | 8.5 | 104.3** | 0.65** | 4.6 | 12.3 |
| P-4010 (30; i.p.) | 8.5 | 114.9 | 0.72** | 4.9 | 13.5 | ||
| P-4010 (15; i.p.) | 7.4 | 110.2** | 0.78 | 4.2 | 14.9 | ||
| Placebo (i.p.) | 8.7 | 162.1 | 1.15 | 6.1 | 18.6 | ||
| 6 | 12 | P-4010 (200; o.g.) | 10.0 | 69.3 | 0.26 | 2.2 | 6.9 |
| P-4010 (100; o.g.) | 9.5 | 80.1 | 0.25 | 3.4 | 8.5 | ||
| P-4010 (50; o.g.) | 9.8 | 122.0 | 0.35 | 4.0 | 12.4 | ||
| Placebo (o.g.) | 9.6 | 103.1 | 0.50 | 4.3 | 10.7 | ||
| 7 | 36 | P-4010 (300; o.g.) | 7.1 | 30.1** | 0.16** | 0.9 | 4.2 |
| Placebo (o.g.) | 7.7 | 56.1 | 0.28 | 1.6 | 7.3 | ||
a
Dose shown as milligrams per kilogram per day; administered i.p. or by oral gavage (o.g.).
b
Ratio of mean total CLS to duration of symptoms.
c
* and **, values shown are significantly lower (*, P < 0.005; **, P < 0.05) than those observed for the placebo groups; † and ‡, values shown are significantly lower (†, P < 0.05; ‡, P < 0.005) than those observed for the ACV groups.